EDIT News and Press, Editas Medicine Inc. From 11/02/22

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITH...

Editas Medicine ( NASDAQ: EDIT ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, before market open. The consensus EPS Estimate is -$0.85 (-49.1% Y/Y) and the consensus Revenue Estimate is $5.12M (-17.3% Y/Y). Over the last 1 year, EDIT has b...

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Editas Medicine ( NASDAQ: EDIT ) rose 4.2% on a report that the CRISPR gene editing company is in advanced talks for the sale of its preclinical oncology lineup, according to Endpoint News. Last month, Editas Medicine was started at neutral at BofA due to competi...

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 adva...

BofA Securities has initiated Editas Medicine with a neutral rating saying that the company's hemoglobinopathies gene editing candidates face stiff competition. The firm has an $18 price target (~34% upside based on Wednesday's close). The company's lead asset, EDIT-301, is in...

Editas Medicine, Inc. (EDIT) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022, 10:30 AM ET Company Participants Gilmore O’Neill - President and Chief Executive Officer Mark Shearman - Executive Vice President and Chief Scientific...

Editas Medicine, Inc. (EDIT) 2022 Wells Fargo Healthcare Conference September 07, 2022 01:55 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Mark Shearman - Chief Scientific Officer Conference Call Participants Yanan Zhu - Wells Fargo...

Summary Editas' engraftment trial experiment made positive headway in Q2 2022 after a patient was successfully treated for sickle cell disease. Editas Medicine is expected to announce the top-line clinical results for the RUBY trial by the end of 2022. Editas Medicine has a hi...